Xilio Therapeutics has reported promising results from its Phase 2 clinical trial involving vilastobart, a novel immunotherapy targeting metastatic microsatellite stable colorectal cancer (MSS CRC).

The trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics. It also showed that KER-065 was generally well-tolerated, with no serious adverse events or dose ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, One2Treat, discusses the company's main goals for attending the SCOPE Summit, ...

CONSHOHOCKEN, Pa. and KING OF PRUSSIA, Pa., Jan. 13, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and ...

CONSHOHOCKEN, Pa. and KING OF PRUSSIA, Pa., Jan. 13, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 ...

Clinical Trial Design & Interim Data from 4D-150 SPECTRA Part 1 Clinical Trial: Objectives: Evaluate safety and tolerability and identify dose level for further evaluation; Utilized stringent ...